GlycoNex, Inc.

As of June 30, 2026, GlycoNex, Inc. carries a market capitalization of 2.88B, placing it among publicly traded companies globally. Its enterprise value stands at 2.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GlycoNex, Inc. has 112.52M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 128.34, and the price-to-book ratio stands at 3.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 125.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.79B versus a market cap of 2.88B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GlycoNex, Inc. maintains a current ratio of 10.45, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.45, indicating elevated leverage, while an interest coverage ratio of -22.57 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GlycoNex, Inc. posted a negative return on equity (ROE) of -29.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.25, reflecting losses generated across the asset base. The company generates approximately 453,285.71 in revenue per employee across its workforce of 49.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, GlycoNex, Inc. recorded 36,000.00 in income tax expense. The company reported a pretax loss of -270.36M and -270.39M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, GlycoNex, Inc.'s stock has declined approximately 11.36% over the past 52 weeks. The 50-day moving average sits at 22.20, while the 200-day moving average is 24.34.

Over the twelve months ended June 30, 2026, GlycoNex, Inc. generated 22.21M in revenue and converted that into -270.39M in net income, yielding earnings per share of -2.43. EBITDA reached -262.33M, while operating income came in at -298.29M.

As of June 30, 2026, GlycoNex, Inc. holds 567.78M in cash and equivalents against 480.20M in total debt, resulting in a net debt position of 45.18M. Total book value stands at 850.74M, with working capital of 543.23M providing operational flexibility.

GlycoNex, Inc. produced -196.01M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.21M in capital expenditures, free cash flow totaled -201.22M - equivalent to -1.81 per share.

Over the twelve months ended June 30, 2026, GlycoNex, Inc. posted a gross margin of 41.17, reflecting its pricing power and cost economics. The operating margin of -1,342.98 and net profit margin of -1,217.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.78, meaning GlycoNex, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

GlycoNex, Inc.'s most recent stock split took place on September 24, 2025.

As of June 30, 2026, GlycoNex, Inc. has an Altman Z-Score of 2.71, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.